



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti- Fusion glycoprotein F0 [PIA174] Standard Size Ab04445-10.0

Isotype and Format: Human IgG1, Kappa

Clone Number: PIA174

Alternative Name(s) of Target: F; Protein F; Human respirovirus 3

UniProt Accession Number of Target Protein: A0A059QA82

Published Application(s): in vitro, neutralization, SPR, ELISA

Published Species Reactivity: Human respirovirus

Immunogen: The original antibody was raised by isolating it from a B cell culture supernatant.

Specificity: This antibody is specific for DIII domain of fusion glycoprotein F0 from human respirovirus 3.

Application Notes: The original antibody was used for an ELISA on parainfluenza virus type 3. Further the structure of this antibody was determined using cryo-EM (Stewart-Jones et al., 2018; PMID:30420505). This antibody was used for a plaque reduction assay on Vero cells infected with parental or escape variant of human respirovirus. This antibody was used for a neutralization assay. It showed here that it disrupted the formation of the HN/F complex (Marcink et al., 2023; PMID:36763666). This antibody was used for surface plasmon resonance on LuS-N71-SpyLinked-PIV3 F (Zhang et al., 2020; PMID:33097791).

Antibody First Published in: Stewart-Jones et al. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4 Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270. [PMID:30420505](#)

Note on publication: To obtain a vaccine effective against all four PIV types, the original paper engineered mutations in each of the four PIV fusion (F) glycoproteins to stabilize their metastable prefusion states, as such stabilization had previously enabled the elicitation of high-titer neutralizing antibodies against the related respiratory syncytial virus.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic

procedures for humans or animals.